溶血指数:能否不加批判地信任制造商的声明?
该描述性研究于2025年2月至4月比较了雅培、贝克曼库尔特、BioSystems、罗氏和西门子五家主要制造商对72项临床生化项目的溶血干扰数据,并将制造商说明书与CLSI C56-A指南进行对比。结果显示制造商对CLSI指南的依从性差异显著,西门子依从性最高,BioSystems未报告任何检测参数的分析物浓度,且许多制造商使用任意阈值如10%偏倚。结论指出制造商说明书常缺乏完整性和一致性,临床实验室必须独立验证溶血阈值。
要点
- 制造商说明书对溶血干扰的報告常不完整、不一致,不可不加批判地信任。
- 临床实验室应独立验证溶血指数阈值,并结合制造商数据、研究和本地验证。
- 溶血是临床生化常见分析前干扰,影响可达3.3%的常规样本,约占拒收标本的60%。
核心结论
- 制造商说明书常缺乏完整性和一致性,临床实验室必须独立验证溶血阈值。
- 需要采用协调一致的方法,结合制造商数据、研究和本地验证,以提高实验室质量并确保符合法规标准。
研究设计与样本
- 描述性研究,于2025年2月至4月进行。
- 比较了72项临床生化项目在雅培、贝克曼库尔特、BioSystems、罗氏和西门子五家主要制造商间的溶血干扰数据。
- 审查制造商包装说明书并与CLSI C56-A溶血干扰测试指南进行对比。
主要发现
- 制造商对CLSI指南的依从性差异显著。
- 西门子依从性最高,在46/71的情况下报告了两个分析物水平的溶血干扰。
- BioSystems未报告任何测试参数的分析物浓度。
- 显著干扰的标准常常缺失,许多制造商使用任意阈值如10%偏倚。
- 接受标准和报告的偏倚值在制造商间不一致,仅雅培和西门子提供了详细的偏倚数据。
临床怎么用
- 临床实验室不应不加批判地信任制造商声明的溶血指数阈值,应进行独立验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hemolysis is a common preanalytical interference in clinical biochemistry, affecting up to 3.3 % of routine samples and contributing to approximately 60 % of rejected specimens. It results from the release of intracellular constituents, such as hemoglobin and potassium, into the plasma due to cell membrane disruption. This interference is often evaluated through hemolysis index (HI) thresholds defined by in vitro diagnostic (IVD) analyzers, but these thresholds may not align with clinical needs or biological variation. METHODS: A descriptive study was conducted from February to April 2025, comparing the hemolysis interference data of 72 clinical chemistry analytes across five major manufacturers: Abbott, Beckman Coulter, BioSystems, Roche, and Siemens. Manufacturer package inserts were reviewed and compared to the CLSI C56-A guideline for hemolysis interference testing. RESULTS: The compliance of manufacturers with the CLSI guideline varied significantly. Siemens had the highest compliance, reporting hemolysis interference at two analyte levels in 46/71 of cases, while BioSystems did not report analyte concentrations for any tested parameters. Criteria for significant interference was often missing, and in many cases, manufacturers used arbitrary thresholds, such as 10 % bias. Additionally, acceptance criteria and reported bias values were inconsistent across manufacturers, with only Abbott and Siemens providing detailed bias data. CONCLUSIONS: Manufacturer instructions often lack completeness and consistency, making it crucial for clinical laboratories to independently validate hemolysis thresholds. A harmonized approach, incorporating manufacturer data, research, and local validation, is essential to improve laboratory quality, minimize misinterpretations, and ensure compliance with regulatory standards.
引用
- Vrtaric A, Miler M, Nikolac Gabaj N, et al. Hemolysis index. Can we uncritically trust manufacturer declarations? Clin Chem Lab Med. 2025. PMID: 41126781. doi:10.1515/cclm-2025-1302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。